Main
lobular breast cancer, tumor, breast cancer
DISEASE PROGRESSION, TUMOR, BREAST CANCER
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, comprising approximately 10–15% of casesPatients with ERSeveral groups have shown that, based on transcriptomic profiling, a subgroup of ILCs can be characterized as immune related, with high levels of immune-related genes, expression of immune checkpoints and lymphocytic infiltrationPrevious data indicate synergy between platinum compounds and ICB in genetically engineered mouse models for ILCHere, we report the clinical and translational results of stage I of the GELATO trial, in which patients with metastatic ILC were treated with anti-PD-L1 until disease progression, combined with low-dose carboplatin as immune induction. To dissect the immunomodulatory effects of carboplatin alone and in combination with anti-PD-L1, we profiled immune cells in the circulation and in the tumor microenvironment of longitudinal biopsies of metastatic lesions. Besides PD-L1 expression, stromal tumor-infiltrating lymphocyte (sTIL) and CD8